In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Sientra (SIEN – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $0.98.
According to TipRanks, Vendetti is a 4-star analyst with an average return of 3.5% and a 38.01% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Nephros, ReShape Lifesciences, and Aethlon Medical.
Currently, the analyst consensus on Sientra is a Moderate Buy with an average price target of $4.00, a 307.29% upside from current levels. In a report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $3.00 price target.
SIEN market cap is currently $61.52M and has a P/E ratio of -2.10.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System, consisting of a console and a handheld device which uses consumable single-use bioTips. The company was founded by Hani M. Zeini in August 29, 2003 and is headquartered in Santa Barbara, CA.
Read More on SIEN:
- Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and Processa Pharmaceuticals (PCSA)
- Analysts Are Bullish on Top Technology Stocks: EzFill Holdings (EZFL), SurgePays (SURG)
- Maxim Group Remains a Hold on VistaGen Therapeutics (VTGN)
- Maxim Group Keeps Their Buy Rating on VirTra (VTSI)
- Maxim Group Remains a Buy on Marpai (MRAI)